ABSTRACT
Emerging evidence indicates that aldosterone and mineralocorticoid receptors (MRs) are associated with the pathogenesis of erectile dysfunction. However, the molecular mechanisms remain largely unknown. In this study, freshly isolated penile corpus cavernosum tissue from rats was treated with aldosterone, with or without MRs inhibitors. Nuclear factor (NF)-kappa B (NF-κB) activity was evaluated by real-time quantitative PCR, luciferase assay, and immunoblot. The results demonstrated that mRNA levels of the NF-κB target genes, including inhibitor of NF-κB alpha (IκB-α), NF-κB1, tumor necrosis factor-alpha (TNF-α), and interleukin 6 (IL-6), were higher after aldosterone treatment. Accordingly, phosphorylation of p65/RelA, IκB-α, and inhibitor of NF-κB kinase-β was markedly increased by aldosterone. Furthermore, knockdown of MRs prevented activation of the NF-κB canonical pathway by aldosterone. Consistent with this finding, ectopic overexpression of MRs enhanced the transcriptional activation of NF-κB by aldosterone. More importantly, the MRs antagonist, spironolactone blocked aldosterone-mediated activation of the canonical NF-κB pathway. In conclusion, aldosterone has an inflammatory effect in the corpus cavernosum penis, inducing NF-κB activation via an MRs-dependent pathway, which may be prevented by selective MRs antagonists. These data reveal the possible role of aldosterone in erectile dysfunction as well as its potential as a novel pharmacologic target for treatment.
Subject(s)
Animals , Male , Rats , Aldosterone/pharmacology , Cytokines/biosynthesis , Gene Knockdown Techniques , I-kappa B Kinase/antagonists & inhibitors , Interleukin-6/genetics , Mineralocorticoid Receptor Antagonists/pharmacology , NF-kappa B/genetics , Penis/metabolism , Protein Serine-Threonine Kinases/antagonists & inhibitors , RNA, Messenger/biosynthesis , Rats, Inbred WKY , Receptors, Mineralocorticoid/genetics , Signal Transduction/drug effects , Spironolactone/pharmacology , Transcriptional Activation , Tumor Necrosis Factor-alpha/biosynthesis , NF-kappaB-Inducing KinaseABSTRACT
Galunisertib (LY2157299), a selective ATP-mimetic inhibitor of TGF-β receptor I (TGF-βRI), is the only known TGF-β pathway inhibitor. In the present study, we investigated the effect of galunisertib on taurocholate (TAC)-induced acute pancreatitis (AP) in rats, and the role of TGF-β and NF-κB signaling pathways. AP was induced by infusion of TAC into the pancreatic duct of Sprague-Dawley male rats (n=30). The rats (220±50 g) were administered galunisertib intragastrically [75 mg·kg-1·day-1 for 2 days (0 and 24 h)]. Serum IL-1β, IL-6, TNF-α, amylase (AMY), lipase (LIP), and myeloperoxidase (MPO) levels were measured by ELISA. NF-κB activity was detected by electrophoretic mobility shift assay (EMSA); NF-κBp65 and TGF-β1 proteins, as well as TGF-βRI and p-Smad2/3 proteins, were detected by western blot assay. Cell apoptosis was detected by TUNEL assay. H&E staining was used to evaluate the histopathological alterations of the pancreas. Galunisertib treatment attenuated the severity of AP and decreased the pancreatic histological score. In addition, number of apoptotic cells were significantly increased in the galunisertib-treated group (16.38±2.26) than in the AP group (8.14±1.27) and sham-operated group (1.82±0.73; P<0.05 and P<0.01, respectively). Galunisertib decreased the expression levels of TGF-βRI and p-Smad2/3 and inhibited NF-κB activation and p65 translocation compared with the sham-operated group. Furthermore, serum IL-1β, IL-6, TNF-α, AMY and LIP levels and tissue MPO activity were significantly decreased in the galunisertib-treated group. Our data demonstrate that galunisertib attenuates the severity of TAC-induced experimental AP in rats by inducing apoptosis in the pancreas, inhibiting the activation of TGF-β signals and NF-κB as well as the secretion of pro-inflammatory cytokines.
Subject(s)
Animals , Male , Pancreatitis/drug therapy , Pyrazoles/therapeutic use , Quinolines/therapeutic use , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Kinase Inhibitors/therapeutic use , Pancreas/drug effects , Pancreas/pathology , Pancreatitis/pathology , Enzyme-Linked Immunosorbent Assay , Blotting, Western , Acute Disease , Interleukin-6/blood , Treatment Outcome , Apoptosis , Peroxidase/analysis , In Situ Nick-End Labeling , Electrophoretic Mobility Shift Assay , Interleukin-1beta/blood , Amylases/blood , Lipase/bloodABSTRACT
We aimed to verify doctor's perception of the qualitative research method, via a qualitative study of interviews with questions on the academic profile of doctors and on the methodology. We interviewed 42 professionals, of which 18 had experience with the qualitative method and 24 with the quantitative method. The results showed that knowledge on the qualitative method was virtually nil among "quantitative researchers", who did not value qualitative research, although some of those realized that it would be important to be more accepting in clinical practice. Others only considered the method as subsidiary to quantitative. The majority considered qualitative methods as lacking academic structure, taking too long to conduct empirical studies, and being difficult to publish. All of them criticized the misuse of the method, and the "quantitatives" pointed out the problem of being unable to reproduce. We concluded that widening the use of the qualitative method by doctors requires investment from the beginning of the academic career and participation in qualitative research projects.
El objetivo es verificar la percepción de médicos sobre el método de investigación cualitativa. Se trata de un estudio cualitativo por medio de entrevistas con preguntas sobre el perfil de los médicos y sobre el método. Entrevistamos a 42 profesionales, 18 con experiencia en el método cualitativo y 24 con el cuantitativo. Los resultados mostraron que el conocimiento sobre lo cualitativo es casi nulo entre los "cuantitativistas", que no valoran la investigación cualitativa, aunque algunos se dan cuenta de que sería importante tener un enfoque más amplio en la práctica clínica. Otros la ven como subsidiaria a lo cuantitativo. Sus dificultades para utilizar ese abordaje son: falta de formación, cantidad de tiempo que exigen y problemas de publicación. Todos han criticado el mal uso del método. Los "cuantitativistas" han destacado como fragilidad, la no reproductibilidad. Llegamos a la conclusión de que para ampliar el uso de los abordajes cualitativos entre los médicos es importante invertir en su formación desde el inicio del curso y la participación en proyectos de investigación cualitativa.
Objetivamos verificar a percepção de médicos sobre o método qualitativo de pesquisa. Estudo qualitativo por meio de entrevistas com questões sobre o perfil acadêmico do médico e perguntas abertas a respeito do método. Entrevistamos 42 profissionais, sendo 18 com experiência no método qualitativo e 24 com o quantitativo. Os resultados evidenciaram que o conhecimento sobre o qualitativo é quase nulo entre os pesquisadores "quantitativistas", os quais não valorizam a pesquisa qualitativa, embora alguns percebam que seria importante ter uma postura mais compreensiva na prática clínica. Outros só a veem como subsidiária ao quantitativo. As principais dificuldades da maioria são: falta de formação, tempo longo despendido nos estudos empíricos e dificuldade de publicação. Todos os entrevistados criticaram o mau uso do método, e os "quantitativistas" ressaltaram, como problema, sua não reprodutibilidade. Concluímos que ampliar o uso do método qualitativo por médicos exige investimento na formação desde o início da graduação e participação em projetos de pesquisa qualitativa.
Subject(s)
Animals , Humans , Mice , Anilides/pharmacology , Benzodiazepinones/pharmacology , /pharmacology , Protein Kinase Inhibitors/pharmacology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Pyrimidines/pharmacology , Repressor Proteins/antagonists & inhibitors , Cells, Cultured , Cell Movement/drug effects , Cell Proliferation/drug effects , Drug Evaluation, Preclinical , Enzyme Activation/drug effects , Neoplasms/pathology , Protein Kinases/genetics , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Protein Serine-Threonine Kinases/physiology , Repressor Proteins/agonists , Repressor Proteins/genetics , Substrate Specificity , Tumor Suppressor Proteins/physiologyABSTRACT
Background: In 2007, a Clinical-Case-Portfolio (CCP) was introduced as a new assessment instrument for fourth grade undergraduate medical students. Since then, several changes have been implemented such as reduction on the number of clinical cases, peer review and the introduction of virtual patient to the portfolio. Aim: To describe the virtual patient model incorporated to the CCP and assess the perception of this change and its effects on the performance of undergraduate students. Material and Methods: Virtual patients were implemented based on prototype clinical cases with specific syndromes. Students perceptions about CCP before and after the introduction of virtual patients were evaluated using a validated questionnaire that was answered voluntarily and anonymously. Results: Overall perception of CCP significantly improved after the incorporation of virtual patients (97.1 ± 24.9 and 111.3 ± 25.7 points; 57.8 and 66.2% respectively). The same improvements were observed for the domains Student Learning, Organization and Evaluation, Teaching Methodology and Integration. In both years, students obtained high grades in CCP evaluations. However CCP grades were not significantly correlated with integrated final grades. Conclusions: The incorporation of virtual patients improved undergraduate students perception of CCP.
Subject(s)
Animals , Mice , Apoptosis , Axin Protein/metabolism , Enzyme Activation , Poly(ADP-ribose) Polymerases/metabolism , Protein Serine-Threonine Kinases/antagonists & inhibitors , Adenosine Triphosphate/metabolism , Apoptosis Inducing Factor/genetics , Apoptosis Inducing Factor/metabolism , Aurora Kinases , Cell Line , Cell Membrane/metabolism , Cell Membrane/physiology , Mitochondria/metabolism , Protein Kinase Inhibitors/pharmacology , RNA Interference , Time-Lapse ImagingABSTRACT
Nek2A is an essential component of cell cycle progression. It regulates the reorganization of the microtubule network at the G2/M transition and controls the centriole-centriole linkage of the cells entering mitosis. The overexpression of Nek2A coding gene has been widely reported in several cancer-associated disorders. In order to design a potent inhibitor and to control its expression mechanism, it is important to understand the structural orientation and the underlying molecular mechanisms associated with its activity regulation. In this study we have summarized the important information that will help in understanding the functional and activity regulation of Nek2A splice variants, which will further facilitate in designing a potent inhibitor against the cancer associated cases. We have also presented previously reported studies on the domain specifications and inhibitor biosynthesis that provide an insight into its specific target residue regions for developing active and more potent inhibitors
Subject(s)
Protein Serine-Threonine Kinases/antagonists & inhibitors , Review Literature as TopicABSTRACT
Uno de los objetivos del tratamiento antihipertensivo, más allá de normalizar las cifras tensionales, es disminuir/regresar el remodelado patológico hipertensivo cardiovascular y renal, de manera de reducir eficientemente el riesgo dado por esta patología. Al respecto, la vía de señalización intracelular de la Rho kinasa (ROCK) es un mecanismo de vasoconstricción y de promoción de remodelado que podría ser un blanco atractivo en el tratamiento antihipertensivo. Objetivo: Evaluar a nivel vascular los niveles de TGF beta, la expresión génica vascular de NADPH oxidasa (fuente de stress oxidativo vascular), y el grado de inflamación parietal y su dependencia de ROCK en la hipertensión arterial (HTA) experimental. Métodos: Se compararon 5 grupos experimentales. Se usó el modelo de HTA por administración de deoxicorticosterona (DOCA, 100mg/Kg, sc una vez/semana) + sal en ratas Sprague Dawley uninefrectomizadas. Como controles, se usaron ratas uninefrectomizadas (Sham). Las ratas DOCA se randomizaron para recibir el inhibidor específico de ROCK fasudil (Fas, 50 mg/kg/d, por gavage, durante 3 semanas), desde la semana 3 post cirugía, o candesartán (Cand, 10 mg/kg/d, por gavage, durante 3 semanas), o fasudil (25 mg/kg/d) + candesartan (5 mg/ kg/d por gavage, 3 semanas ). Al finalizar los experimentos se midieron en la aorta los niveles de MYPT1 fosforilada/total, blanco de ROCK y estimador de su activación (por Western blot), de TGF beta (por Western blot), los niveles de mRNA de las subunidades p22 Phox y gp 91 de la NADPH oxidasa (por RT PCR) y el número de células infamatorias ED1 en anillos aórticos (por inmunohistoquímica). Resultados: La presión arterial sistólica aumentó en las ratas DOCA a 172 +/- 7 mm Hg (p < 0,05) y fue normalizada después de 3 semanas de tratamiento con candesartán, fasudil y de candesartán + fasudil. La actividad de ROCK en aorta aumentó en 4 veces en las ratas hipertensas (p < 0,05)...
Background: Rho kinase (ROCK) activity promotes vasoconstriction and pathological vascular remodeling in experimental hypertension. Our working hypothesis is that ROCK inhibition could be an attractive target to prevent vascular remodeling in hypertension. Objectives: We evaluated vascular TGF beta, the genic expression of NADPH oxydase (a vascular oxidative stress source) and its dependency from ROCK activation in experimental hypertension in the rat. Methods: Five experimental groups were compared. Hypertension was induced by the administration of salt and deoxycorticosterone acetate (DOCA, 100 mg/Kg, weekly) to unilaterally nephrectomized rats. Unilaterally nephrectomized rats were used as controls (controls). DOCA rats were randomized to receive either Fasudil (a ROCK inhibitor, 50 mg/Kg/day) or candesartan (CAND, 10 mg/Kg/day for 3 weeks), starting 3 weeks after surgery. The other group received fasudil (25 mg/Kg/day) plus CAND (5 mg/Kg/day) for 3 weeks. After treatment, phosphorilated MYPT1 (a ROCK target expressing ROCK activation) was measured in aortic wall rings by Western Blot. We also determined TGF-beta (Western Blot), p22 Phox and gp 91subnits of NADPH oxydase mRNA (RT-PCR) and the number of ED1 infammatory cells. Results: In DOCA rats, SBP increased to 172 +/- 7 mm Hg (p < 0,05), and returned to normal values after 3 weeks with candesartan, fasudil or both combined. In these rats, ROCK activity in aorta was increased 4 times (p < 0,05) and returned to control values in the 3 groups receiving treatment. p22 Phox and gp 91subnits of NADPH oxydase mRNA were increased by 80 and 90 percent, respectively (p<0,05). These changes were reduced to control values in rats receiving fasudil and candesartan + fasudil. Gene expression of TGF-beta increased 4 times, and the number of ED1...
Subject(s)
Animals , Rats , /administration & dosage , Antihypertensive Agents/administration & dosage , Benzimidazoles/administration & dosage , Hypertension/drug therapy , rho-Associated Kinases/antagonists & inhibitors , Tetrazoles/administration & dosage , /analogs & derivatives , Blotting, Western , Enzyme Inhibitors , Gene Expression , Protein Kinase Inhibitors , NADPH Oxidases/genetics , NADPH Oxidases/metabolism , Polymerase Chain Reaction , Protein Serine-Threonine Kinases/antagonists & inhibitors , Rats, Sprague-Dawley , RNA, Messenger , Transforming Growth Factor betaABSTRACT
Insufficient intracellular fat oxidation is an important contributor to aging-related insulin resistance, while the precise mechanism underlying is unclear. AMP-activated protein kinase (AMPK) is an important regulator of intracellular fat oxidation and was evidenced to play a key role in high-glucose and high-fat induced glucose intolerance. In the present study, we investigated whether altered AMPK expression or activity was also involved in aging-related insulin resistance. Insulin sensitivity of rats' skeletal muscles was evaluated using in-vitro glucose uptake assay. Activity of alpha subunit of AMPK (AMPKalpha) was evaluated by measuring the phosphorylation of both AMPKalpha (P-AMPKalpha) and acetyl-CoA carboxylase (P-ACC), while expression of AMPKalpha was assessed by determining the mRNA levels of AMPKalpha1 and AMPKalpha2, and protein contents of AMPKalpha. Compared with 4-month old rats, 24-month old rats exhibited obviously impaired insulin sensitivity. At the same time, AMPKalpha activity significantly decreased, while AMPKalpha expression did not alter during aging. Glucose transporter 4 expression also decreased in old rats. Compared with 24-month old rats, administration of the specific activator of AMPK, 5-aminoimidazole-4-carboxamide riboside (AICAR), significantly elevated AMPKalpha activity and GluT4 expression. Also, aging-related insulin resistance was significantly ameliorated by AICAR treatment. In conclusion, aging-related insulin resistance is associated with impaired AMPKalpha activity and could be ameliorated by AICAR, thus indicating a possible role of AMPK in aging-induced insulin resistance.
Subject(s)
Animals , Male , Rats , AMP-Activated Protein Kinases , Acetyl-CoA Carboxylase/metabolism , Aging/physiology , Aminoimidazole Carboxamide/analogs & derivatives , Glucose/metabolism , Glucose Transporter Type 4/metabolism , Insulin/blood , Insulin Resistance , Multienzyme Complexes/antagonists & inhibitors , Muscle, Skeletal/metabolism , Phosphorylation , Protein Serine-Threonine Kinases/antagonists & inhibitors , Rats, Wistar , Ribonucleotides/pharmacologyABSTRACT
Antirheumatic gold compounds have been shown to inhibit NF-kB activation by blocking IkB kinase (IKK) activity. To examine the possible inhibitory mechanism of gold compounds, we expressed wild type and mutant forms of IKk alpha and beta subunits in COS-7 cells and determined the effect of gold on the activity of these enzymes both in vivo and in vitro. Substitution of Cys-179 of IKK beta with alanine (C179A) rendered the enzyme to become resistant to inhibition by a gold compound auranofin, however, similar protective effect was not observed with an equivalent level of IKK alpha (C178A) mutant expressed in the cells. Auranofin inhibited constitutively active IKK alpha and beta and variants; IKK alpha (S176E, S180E) or IKK beta (S177E, S181E), suggesting that gold directly cause inhibition of activated enzyme. The different inhibitory effect of auranofin on IKK alpha (C178A) and IKK beta (C179A) mutants indicates that gold could inhibit the two subunits of IKK in a different mode, and the inhibition of NF- kB and IKK activation induced by inflammatory signals in gold-treated cells appears through its interaction with Cys-179 of IKK beta.
Subject(s)
Animals , Amino Acid Substitution , Auranofin/pharmacology , COS Cells , Cysteine/genetics , Enzyme Activation/drug effects , Gold Compounds/pharmacology , Protein Subunits/chemistry , Protein Serine-Threonine Kinases/antagonists & inhibitors , Sulfhydryl Compounds/pharmacologyABSTRACT
Repetitive low dose thioacetamide (TA) treatment of hepatocytes was found to induce cells in G2 arrest. In the present study, an attempt was made to investigate alterations in expression of cell cycle regulators after G1 progression in the same repetitive low dose TA treated hepatocytes system and to define the determinators involved in G2 arrest. TA was daily administered intraperitoneally, with a dose of 50 mg/kg for 7 days. Expression levels of cyclin E and CDK2 were similar, increased at day 1 and reached a peak at day 2. And they recycled from day 3 reaching a second peak at day 5. Expression level of cyclin A was similar to p27(Kip1) and p57(Kip2) but not to CDK2 and increased to a peak level at day 2. Expression levels of cyclin B1 and cdc2 were similar although the cyclin B1 level was generally low, decreased from day 1 to basal levels at day 3 and persisted at a low level till day 7. The expression level of cyclin G1 was similar to p53 that peaked at day 3 and again at day 6 elevated over basal level. BrdU-labeled hepatocytic nuclei increased from 12 h, reached a peak at day 2, then decreased, and were not detectable from day 6. The number of PCNA-labeled nuclei increased immediately, peaked at day 2, and maintained till day 7. These results suggest that G2 arrest induced by repeated TA treatment might be p53-dependent, via activation of cyclin G1, rather than inhibition of cyclin B1- cdc2 complex, and inhibitors holding S phase progression might be p27(Kip1) and p57(Kip2).